Drugs / RUCOSOPASEM MANGANESE
last change Jan 2024 re-read 2 minutes ago

RUCOSOPASEM MANGANESE

Other / unclassified

Developed for
non-small cell lung carcinoma · pancreas disorder
Investigated by
Galera Therapeutics, Inc. · Syneos Health

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT03762031 Mar 2019 → Mar 2020 Galera Therapeutics, Inc. Completed No outcome recorded
Phase 1 NCT03099824 Oct 2018 → Jan 2020 Galera Therapeutics, Inc. Completed No outcome recorded
Phase 1 NCT03194139 Sep → Dec 2017 Galera Therapeutics, Inc. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT04476797 Oct 2020 → Nov 2023 non-small cell lung carcinoma Galera Therapeutics, Inc. Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT04698915 May 2021 → Nov 2023 pancreas disorder Galera Therapeutics, Inc. Terminated No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as RUCOSOPASEM MANGANESE ChEMBL registry synonym — accepted as the source's own label CHEMBL4650307
Known as Avasopasem manganese dipropionate ChEMBL registry synonym — accepted as the source's own label CHEMBL4650307
Known as BIS-PROPIONATO(GC4419) ChEMBL registry synonym — accepted as the source's own label CHEMBL4650307
Known as GC-4419 DIPROPIONATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4650307
Known as GC4711 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03099824
4

NCT03762031

NCT04698915

NCT04476797

NCT03194139

Known as rucosopasem Rucosopasem, an investigational selective dismutase mimetic that converts superoxide to hydrogen peroxide” PMID 38264869 Jan 2024
Modality Other / unclassified “Rucosopasem, an investigational selective dismutase mimetic” PMID 38264869 Jan 2024
Route Oral “when given as an oral capsule” NCT03099824